NEW YORK TRANSCATHETER VALVES 2018

New York, NY
December 6, 2018

Target Audience

This educational program has been designed to meet the educational needs of interventional cardiologists, invasive cardiologists, cardiac surgeons, interventional fellows in training, radiologists, nurses, technicians and other allied health care professionals who work in structural heart disease.

Educational Goal

The New York Transcatheter Valves 2018 will provide health care providers with current and emerging approaches in the diagnosis, management and treatment of valvular and structural heart disease.

Learning Objectives

  • Appraise new and upcoming technologies in the management of structural heart disease to determine their benefit for patients
  • Compare the applications of cardiac CT and MRI in structural heart disease
  • Present indications, techniques, outcomes, and complications for transcatheter valve intervention in patients with native valve disease and bioprostectic valve dysfunction
  • Examine best practice techniques new heart valve implantation
  • Evaluate the rationale, challenges, and necessity of the heart team approach to valvular heart disease, and the functionality of the team within a center of excellence
  • Evaluate the barriers to care in patients with valvular heart disease with specific attention to current gaps in the timely delivery of percutaneous and surgical interventions

Accreditation

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of CMEsolutions and Gaffney Events. The CMEsolutions is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The CMEsolutions designates this live activity for a maximum of 7.75 AMA PRA Category 1 Credits.™ Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Participation Requirements

  1. Complete sign in sheet
  2. Attend accredited sessions
  3. For credit log on to URL: http://online-med-edu.com/nyv2018/ (you are here)
  4. Complete evaluation, credit request form, and download or print credit statement

Faculty and Disclosures

CMEsolutions requires everyone in a position to control the content of this activity to disclose any relevant financial conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by CMEsolutions for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

Directors

Samin K. Sharma, MD, FACC, FSCAI
Director, Clinical & Interventional Cardiology, The Mount Sinai Hospital
New York, NY
Samin K. Sharma has disclosed the following relevant financial relationships: Abbott Vascular, Boston Scientific, Cardiovascular Systems Inc.-Speaker Bureau

Gilbert H. Tang, MD, MSc, MBA, FACC, FRCSC
Surgical Director, Structural Heart Program, The Mount Sinai Hospital
New York, NY
Gilbert H. Tang has disclosed the following relevant financial relationships: Edwards Lifescience, Medtronic-Physician Proctor; Abbott-Consultant

Annapoorna S. Kini, MD, MRCP, FACC
Interventional Director, Structural Heart Program, The Mount Sinai Hospital
New York, NY
Annapoorna S. Kini has no relevant financial relationships to disclose.

Course Advisors

David H. Adams, MD
Cardiac Surgeon-in-Chief, The Mount Sinai Hospital
New York, NY
David H. Adams has disclosed the following relevant financial relationships: Edwards Lifesciences- The Icahn School of Medicine at Mount Sinai receives royalty payments from Edwards Lifesciences for intellectual property related to development of valve repair rings; Medtronic- The Icahn School of Medicine at Mount Sinai receives royalty payments from Edwards Lifesciences for intellectual property related to development of valve repair rings, Research Support, National Co-PI for the Medtronic CoreValve US Pivotal Trial and the Medtronic APOLLO FDA Pivotal Trial

Roxana Mehran, MD, MSCAI, FACC, FESC
Director of Interventional Cardiovascular , Research and Clinical Trials
Icahn School of Medicine at Mount Sinai
New York, NY
Roxana Mehran has disclosed the following relevant financial relationships: Abbott Laboratories, Abiomed (spouse), BMS, Boston Scientific, Cardiovascular Systems Inc., Medscape-Consultant; Astra Zeneca, Bayer, Beth Israel Deaconess Medical Center, BMS, Boston Scientific, CSL Behring, Eli Lilly/DSI, Novartis Pharmaceuticals, Medtronic -Research Support

Co-Directors

Anelechi C. Anyanwu, MD
Surgical Director, Mechanical Circulatory, Support and Heart Transplant Program, The Mount Sinai Hospital
New York, NY
Anelechi C. Anyanwu has no relevant financial relationships to disclose.

George D. Dangas, MD, PhD, MSCAI, FACC
Director, Cardiovascular Innovation, The Mount Sinai Hospital
New York, NY
George Dangas has disclosed the following relevant financial relationships: Bayer, Daichii Sankyo - Consultant

Asaad A. Khan, MD, MRCP
Assistant Director, Interventional Structural Heart Disease Program
The Mount Sinai Hospital
New York, NY
Asaad Khan has no relevant financial relationships to disclose.

Jason Kovacic, MD, PhD
Associate Professor of Medicine, The Mount Sinai Hospital
New York, NY
Jason Kovacic has no relevant financial relationships to disclose.

Stamatios A.Lerakis, MD, PhD, FACC, FASE
Director, Non-invasive Cardiology, The Mount Sinai Hospital
New York, NY
Stamatios Learkis has no relevant financial relationships to disclose.

Faculty

Alexandre Abizaid, MD, PhD, FACC
Director of Invasive Cardiology, Dante Pazzanese Institute of Cardiology
São Paulo, Brazil
Alexandre Abizaid has disclosed the following relevant financial relationship: Boston Scientific-Consultant

Vinayak N. Bapat, MD
Director, Transcatheter Valve Therapy, New York-Presbyterian Hospital
New York, NY
Vinayak Bapat has disclosed the following relevant financial relationships; Medtronic Inc.-Speaker Honoraria

Robert O. Bonow, MD, MS
Vice Chair for Development and Innovation, Northwestern University Feinberg School of Medicine
Chicago, IL
Robert Bonow has no relevant financial relationships to disclose.

Antonio Colombo, MD
Director, Cardiac Cath Lab, EMO GVM Centro Cuore Columbus and San Raffaele Hospital
Milan, Italy
Antonio Colombo has no relevant financial relationships to disclose.

Eberhard Grube, MD
Head CIIC, University of Bonn
Bonn, Germany
Eberhard Grube has disclosed the following relevant financial relationships: Boston Scientific, Claret Medical Inc., Highlife, InSeal Medical, LivaNova, Medtronic, Mitra/Trialign, Shockwave Medical, Valve Medical-Consultant; Pipeline-Speaker’s Bureau, Consulting fees; Valtech-Speaker’s Bureau Consultant

Saibal Kar, MD, FACC, FSCAI
Director, Interventional Cardiac Research, Cedars-Sinai Medical Center
Los Angeles, CA
Saibal Kar has disclosed the following relevant financial relationships: Edwards Life Science- Research Support; Abbott Vascular-Consultant/Advisory Board, Research support; Boston Scientific-Consultant/Advisory Board

Susheel K. Kodali, MD, FACC
Director, Heart & Valve Center, Columbia University Medical Center
New York, NY
Susheel Kodali has disclosed the following relevant financial relationships: Abbott, Claret Medical Inc., Merrill Life Sciences -Consultant/Advisory Board

Martin B. Leon, MD
Director, Center for Interventional Cardiology, Columbia University Medical Center
New York, NY
Martin Leon has no relevant financial relationships to disclose.

Barry A. Love, MD, FRCPC
Director, Congenital Cardiac Cath Lab, The Mount Sinai Hospital
New York, NY
Barry Love has no relevant financial relationships to disclose.

Raj Makkar, MD, FACC, FSCAI
Director, Interventional Cardiology and Cardiac Cath Lab, Cedars-Sinai Medical Center
Los Angeles, CA
Raj Makkar has disclosed the following relevant financial relationships: Edwards Life Sciences, Abbott, Medtronic-Consultant/Advisory Board, Research Support; Claret Medical Inc.- Consultant/Advisory Board

Ravinder Singh Rao, MD
Director, TAVR and Structural Heart Disease, Eternal Hospital
Jaipur, India
Ravinder Singh Rao has no relevant financial relationships to disclose.

Gian Paolo Ussia, MD, FACC, FSCAI
Director, Interventional Cath Lab, University Campus Bio-Medico di Roma
Rome, Italy
Gian Ussia has disclosed the following relevant financial relationships: Abbott St. Jude Medical- Physician Proctor

Planner Disclosures

No member of CMEsolutions or Gaffney Events has any relevant financial relationships to disclose.

Fees

There is a registration fee associated with this CME activity as outlined on the website.

Off-label Use

New York Transcatheter Valves 2018 may contain discussion of unlabeled and/or investigational uses of agents not approved by the FDA.  Please consult the prescribing information for each product.

Commercial Support

Commercial support for this activity is provided by Abbott Laboratories and by Medtronic.

Privacy Policy

CMEsolutions Privacy and Confidentiality Policy:  www.online-med-edu.com/privacypolicy.pdf
CMEsolutions can be contacted at info@cmesolutions.org.

 

 complete evaluation/credit request